Skip to content

Bioventus BVS Noncontrolling interests in subsidiaries

Noncontrolling interests in subsidiaries at other companies

Enovis logo
EnovisENOV
$2.57M+4.9%
Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
Medtronic logo
MedtronicMDT

Other financials

Income statement

See full
Revenue$132.1M+6.6%
Gross profit$90.8M+9.3%
Operating income$8.4M+72.8%
Net income$3.1M+218%
EPS (diluted)$0.04+200%

Balance sheet

See full
Cash & equivalents$35.8M+57.2%
Total debt$288.4M-21.2%
Total equity$188.9M+27.5%
Total assets$650.5M-5.9%

Cash flow

See full
Operating cash flow$8.9M+146%
CapEx$574.0K-30.5%
Free cash flow$8.4M+141%

Valuation

See full
Market cap$659.19M+51.7%
Enterprise value$911.76M+17.2%
P/E23.1×
P/S1.1×+0.4×

Profitability

See full
Gross margin68.7%+1.2pp
Operating margin10%
Net margin4.9%+3.2pp
FCF margin17.5%+13.2pp

Returns & leverage

See full
Return on equity16.9%+10.9pp
Debt / equity1.5×-0.9×
Current ratio1.7×+0.3×

Where this comes from

Reported directly by Bioventus in its filing.

Tagged under the XBRL concept us-gaap:MinorityInterest.

The official record: Bioventus’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bioventus's noncontrolling interests in subsidiaries.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bioventus's noncontrolling interests in subsidiaries?
Bioventus (BVS) reported noncontrolling interests in subsidiaries of $45.36M in Q1 2026.
How has Bioventus's noncontrolling interests in subsidiaries changed year-over-year?
Bioventus's noncontrolling interests in subsidiaries increased by 21.5% year-over-year, from $37.34M to $45.36M.
What is the long-term trend for Bioventus's noncontrolling interests in subsidiaries?
Over 4 years (2021 to 2025), Bioventus's noncontrolling interests in subsidiaries has grown at a -25.1% compound annual growth rate (CAGR), from $140.69M to $44.34M.
What does noncontrolling interests in subsidiaries mean?
This represents the portion of a subsidiary's net assets that is owned by outside shareholders rather than the parent company. It is reported within equity to show the total value of the subsidiary's assets and liabilities that are not attributable to the parent. It reflects the non-controlling stake in consolidated entities.